Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China · Delayed Price · Currency is CNY 12.46
+0.47 (3.92%)
Jul 25, 2025, 3:00 PM CST
SHA:603567 Revenue
Heilongjiang ZBD Pharmaceutical had revenue of 468.94M CNY in the quarter ending March 31, 2025, a decrease of -58.03%. This brings the company's revenue in the last twelve months to 2.06B, down -31.29% year-over-year. In the year 2024, Heilongjiang ZBD Pharmaceutical had annual revenue of 2.70B, down -13.84%.
Revenue (ttm)
2.06B
Revenue Growth
-31.29%
P/S Ratio
5.69
Revenue / Employee
875.09K
Employees
2,349
Market Cap
11.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.70B | -434.25M | -13.84% |
| Dec 31, 2023 | 3.14B | -1.08B | -25.53% |
| Dec 31, 2022 | 4.21B | 87.33M | 2.12% |
| Dec 31, 2021 | 4.13B | 723.07M | 21.24% |
| Dec 31, 2020 | 3.40B | 111.89M | 3.40% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 39.59B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Aier Eye Hospital Group | 21.81B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |